- Home
- PRPH vs NXTC Comparison
PRPH vs NXTC Comparison
Compare PRPH & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPH
- NXTC
- Stock Information
- Founded
- PRPH 1989
- NXTC 2015
- Country
- PRPH United States
- NXTC United States
- Employees
- PRPH N/A
- NXTC N/A
- Industry
- PRPH Biotechnology: Pharmaceutical Preparations
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- PRPH Health Care
- NXTC Health Care
- Exchange
- PRPH Nasdaq
- NXTC Nasdaq
- Market Cap
- PRPH 10.7M
- NXTC 9.3M
- IPO Year
- PRPH 1997
- NXTC 2019
- Fundamental
- Price
- PRPH $0.37
- NXTC $0.41
- Analyst Decision
- PRPH
- NXTC Strong Buy
- Analyst Count
- PRPH 0
- NXTC 2
- Target Price
- PRPH N/A
- NXTC $3.50
- AVG Volume (30 Days)
- PRPH 748.2K
- NXTC 178.3K
- Earning Date
- PRPH 05-20-2025
- NXTC 05-01-2025
- Dividend Yield
- PRPH N/A
- NXTC N/A
- EPS Growth
- PRPH N/A
- NXTC N/A
- EPS
- PRPH N/A
- NXTC N/A
- Revenue
- PRPH $6,770,000.00
- NXTC N/A
- Revenue This Year
- PRPH $221.82
- NXTC N/A
- Revenue Next Year
- PRPH N/A
- NXTC N/A
- P/E Ratio
- PRPH N/A
- NXTC N/A
- Revenue Growth
- PRPH N/A
- NXTC N/A
- 52 Week Low
- PRPH $0.22
- NXTC $0.22
- 52 Week High
- PRPH $5.62
- NXTC $1.82
- Technical
- Relative Strength Index (RSI)
- PRPH 53.73
- NXTC 45.41
- Support Level
- PRPH $0.30
- NXTC $0.34
- Resistance Level
- PRPH $0.38
- NXTC $0.47
- Average True Range (ATR)
- PRPH 0.04
- NXTC 0.06
- MACD
- PRPH 0.01
- NXTC 0.01
- Stochastic Oscillator
- PRPH 75.27
- NXTC 39.66
About PRPH ProPhase Labs Inc. (DE)
ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.